Emergent BioSolutions (NYSE:EBS) Downgraded to “Hold” Rating by StockNews.com
Emergent BioSolutions (NYSE:EBS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday. Several other equities ...
Leading Factor Driving The Ebanga Market In 2024: Rising Ebola Virus Disease (EVD) Cases Surges Growth
LONDON, GREATER LONDON, UNITED KINGDOM, January 25, 2025 /EINPresswire / -- The ebanga market size has seen significant historical compound annual growth, growing from millions in 2024 to a higher ...
Emergent seeking to reverse fortunes and become a major overdose treatment player
Papa presented the company’s “turnaround plan” for 2025 at J.P. Morgan. “We are focused on first stabilising the company, ...
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ImmunoPrecise Antibodies (IPA – Research ...
HC Wainwright Reiterates “Buy” Rating for Emergent BioSolutions (NYSE:EBS)
Emergent BioSolutions (NYSE:EBS – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have ...